Characteristics associated with maintenance ofmean A1c ,6.5% in people with dysglycemia in the ORIGIN Trial

Diabetes Care

Volumn 36, Issue 10, 2013, Pages 2915-2922

  Riddle, Matthew C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; METFORMIN; OMEGA 3 FATTY ACID; ORAL ANTIDIABETIC AGENT;

ADD ON THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSGLYCEMIA; DYSLIPIDEMIA; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INTENTION TO TREAT ANALYSIS; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; TREATMENT DURATION;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84890446633     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2238     Document Type: Article

References (27)

1. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412
2. Saydah S, Tao M, Imperatore G, Gregg E. GHb level and subsequentmortality among adults in the U.S. Diabetes Care 2009;32: 1440-1446
3. Sarwar N, Gao P, Seshasai SR, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215-2222
4. Gerstein HC, Islam S, Anand S, et al. Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study. Diabetologia 2010; 53:2509-2517
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
6. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865
7. Chew EY, Ambrosius WT, Davis MD, et al.; ACCORD Study Group; ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-244
8. Ismail-Beigi F, Craven T, Banerji MA, et al.; ACCORD Trial Group. Effect of intensive treatment of hyperglycemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376:419-430
9. Hadden DR, Blair ALT, Wilson EA, et al. Natural history of diabetes presenting age 40-69 years: a prospective study of the influence of intensive dietary therapy. Q J Med 1986;59:579-598
10. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44: 1249-1258
11. Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355: 2427-2443
12. The ORIGIN Trial Investigators. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008;155:26-32, 32.e1-e6
13. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367: 319-328
14. ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367:309-318
15. American Diabetes Association. Standards of medical care in diabetesd2012. Diabetes Care 2012;35(Suppl. 1):S11-S63
16. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-559
17. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
18. GersteinHC, MillerME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
19. DuckworthW, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360: 129-139
20. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004;27:1535-1540
21. Brown JB, Conner C, Nichols GA. Secondary failure ofmetforminmonotherapy in clinical practice. Diabetes Care 2010; 33:501-506
22. RiddleMC, YuenKCJ. Reevaluating goals of insulin therapy: perspectives from large clinical trials. EndocrinolMetab Clin North Am 2012;41:41-56
23. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012;35(Suppl. 1):S64-S71
24. World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of aWHO consultation. Available at http://www.who.int/diabetes/publications/ diagnosis-diabetes2011/ en/index.html. Accessed 1 September 2011
25. Rantanen T, Guralnik JM, Foley D, et al. Midlife hand grip strength as a predictor of old age disability. JAMA 1999;281: 558-560
26. Bonnet F, Disse E, Laville M, et al.; RISC Study Group. Moderate alcohol consumption is associated with improved insulin sensitivity, reduced basal insulin secretion rate and lower fasting glucagon concentration in healthy women. Diabetologia 2012;55:3228-3237
27. Miller ME, Bonds DE, Gerstein HC, et al.; ACCORD Investigators. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010; 340:b5444